{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T09:17:02Z","timestamp":1770283022210,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1124\/jpet.114.220558","type":"journal-article","created":{"date-parts":[[2015,1,10]],"date-time":"2015-01-10T05:01:06Z","timestamp":1420866066000},"page":"568-578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["CHF6001 II: A Novel Phosphodiesterase 4 Inhibitor, Suitable for Topical Pulmonary Administration\u2014In Vivo Preclinical Pharmacology Profile Defines a Potent Anti-Inflammatory Compound with a Wide Therapeutic Window"],"prefix":"10.1016","volume":"352","author":[{"given":"Gino","family":"Villetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Carnini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loredana","family":"Battipaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Preynat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Tonino","family":"Bolzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Bassani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Bergamaschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Rita","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Puviani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio Franco","family":"Stellari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Cenacchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Volta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Bertacche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Mileo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Bagnacani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Puccini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Catinella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Facchinetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Sala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Civelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.114.220558_bib1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1021\/jm401549m","article-title":"Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases","volume":"57","author":"Armani","year":"2014","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.114.220558_bib2","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/0006-2952(96)00053-6","article-title":"Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding","volume":"51","author":"Barnette","year":"1996","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.114.220558_bib3","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0022-3565(24)37221-0","article-title":"SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions","volume":"284","author":"Barnette","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.220558_bib4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1164\/rccm.201301-0021PP","article-title":"Phosphodiesterase-4 inhibitor therapy for lung diseases","volume":"188","author":"Begh\u00e8","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1124\/jpet.114.220558_bib5","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1152\/jappl.1988.65.4.1642","article-title":"Antigen challenge of sensitized rats increases airway responsiveness to methacholine","volume":"65","author":"Bellofiore","year":"1988","journal-title":"J Appl Physiol (1985)"},{"key":"10.1124\/jpet.114.220558_bib6","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0022-3565(24)29538-0","article-title":"In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor","volume":"297","author":"Bundschuh","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.220558_bib7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejphar.2006.04.020","article-title":"Temporal profile of forced expiratory lung function in allergen-challenged Brown-Norway rats","volume":"540","author":"Celly","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.114.220558_bib8","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/toxsci\/kfm161","article-title":"Investigation of the molecular mechanisms preceding PDE4 inhibitor-induced vasculopathy in rats: tissue inhibitor of metalloproteinase 1, a potential predictive biomarker","volume":"100","author":"Dagu\u00e8s","year":"2007","journal-title":"Toxicol Sci"},{"key":"10.1124\/jpet.114.220558_bib9","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1021\/jm9505066","article-title":"Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret","volume":"39","author":"Duplantier","year":"1996","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.114.220558_bib10","doi-asserted-by":"crossref","unstructured":"Eltom S, Stevenson C, Birrell MA (2013) Cigarette smoke exposure as a model of inflammation associated with COPD. Curr Protoc Pharmacol 5:Unit5.64.","DOI":"10.1002\/0471141755.ph0564s60"},{"key":"10.1124\/jpet.114.220558_bib11","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/0091-6749(91)90253-K","article-title":"Characterization of allergen-induced bronchial hyperresponsiveness and airway inflammation in actively sensitized brown-Norway rats","volume":"88","author":"Elwood","year":"1991","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl 57","key":"10.1124\/jpet.114.220558_bib12","first-page":"P736","article-title":"Safety, tolerability and pharmacokinetics of a new inhaled once-daily phosphodiesterase (PDE) 4 inhibitor in healthy volunteers","volume":"42","author":"Esposito","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1124\/jpet.114.220558_bib13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejphar.2005.12.059","article-title":"Phosphodiesterase inhibitors in airways disease","volume":"533","author":"Fan Chung","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.114.220558_bib14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2165\/00003495-200059020-00004","article-title":"Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?","volume":"59","author":"Giembycz","year":"2000","journal-title":"Drugs"},{"key":"10.1124\/jpet.114.220558_bib15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/bjp.2008.297","article-title":"Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?","volume":"155","author":"Giembycz","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.114.220558_bib16","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0022-3565(24)29537-9","article-title":"Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro","volume":"297","author":"Hatzelmann","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.220558_bib17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejphar.2011.02.042","article-title":"Disease-modifying effect of ASP3258, a novel phosphodiesterase type 4 inhibitor, on subchronic cigarette smoke exposure-induced lung injury in guinea pigs","volume":"659","author":"Kubo","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.114.220558_bib18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1124\/jpet.103.053942","article-title":"In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration","volume":"307","author":"Kuss","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.220558_bib19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cell.2005.07.030","article-title":"Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias","volume":"123","author":"Lehnart","year":"2005","journal-title":"Cell"},{"key":"10.1124\/jpet.114.220558_bib20","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1164\/rccm.200411-1549OC","article-title":"Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke","volume":"172","author":"Martorana","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1124\/jpet.114.220558_bib21","doi-asserted-by":"crossref","first-page":"7797","DOI":"10.1021\/jm200677b","article-title":"Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease","volume":"54","author":"Millan","year":"2011","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.114.220558_bib22","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/01902140290096728","article-title":"A murine model of cigarette smoke-induced pulmonary inflammation using intranasally administered smoke-conditioned medium","volume":"28","author":"Miller","year":"2002","journal-title":"Exp Lung Res"},{"key":"10.1124\/jpet.114.220558_bib23","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1124\/jpet.114.220541","article-title":"CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration","volume":"352","author":"Moretto","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.220558_bib24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1124\/jpet.110.173641","article-title":"In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor","volume":"337","author":"Nials","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 7","key":"10.1124\/jpet.114.220558_bib25","first-page":"183","article-title":"Phosphodiesterase isozymes involved in regulating acid secretion in the isolated mouse stomach","volume":"60","author":"Okuda","year":"2009","journal-title":"J Physiol Pharmacol"},{"key":"10.1124\/jpet.114.220558_bib26","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1164\/ajrccm\/147.4.967","article-title":"Inflammatory cell populations in the airways and parenchyma after antigen challenge in the rat","volume":"147","author":"Renzi","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"10.1124\/jpet.114.220558_bib27","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/sj.bjp.0704457","article-title":"Assessing the emetic potential of PDE4 inhibitors in rats","volume":"135","author":"Robichaud","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.114.220558_bib28","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0028-3908(00)00142-8","article-title":"PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway","volume":"40","author":"Robichaud","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.114.220558_bib29","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI0215506","article-title":"Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis","volume":"110","author":"Robichaud","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.114.220558_bib30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0028-3908(98)00190-7","article-title":"Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret","volume":"38","author":"Robichaud","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.114.220558_bib31","doi-asserted-by":"crossref","first-page":"14250","DOI":"10.1021\/bi971112e","article-title":"Human recombinant phosphodiesterase 4B2B binds (R)-rolipram at a single site with two affinities","volume":"36","author":"Rocque","year":"1997","journal-title":"Biochemistry"},{"key":"10.1124\/jpet.114.220558_bib32","first-page":"A4175","article-title":"The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatic subjects (Abstract)","volume":"189","author":"Singh","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1124\/jpet.114.220558_bib33","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.2165\/00003495-200363230-00002","article-title":"Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease","volume":"63","author":"Spina","year":"2003","journal-title":"Drugs"},{"issue":"5, Suppl","key":"10.1124\/jpet.114.220558_bib34","doi-asserted-by":"crossref","first-page":"151S","DOI":"10.1378\/chest.121.5_suppl.151S","article-title":"Neutrophils and the pathogenesis of COPD","volume":"121","author":"Stockley","year":"2002","journal-title":"Chest"},{"key":"10.1124\/jpet.114.220558_bib35","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0165-6147(97)90613-1","article-title":"Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?","volume":"18","author":"Teixeira","year":"1997","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/jpet.114.220558_bib36","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1164\/ajrccm.157.2.9708012","article-title":"Phosphodiesterase isozymes: molecular targets for novel antiasthma agents","volume":"157","author":"Torphy","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1124\/jpet.114.220558_bib37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1124\/jpet.110.173690","article-title":"GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization","volume":"337","author":"Tralau-Stewart","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.220558_bib38","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/1465-9921-11-126","article-title":"Pharmacological characterisation of anti-inflammatory compounds in acute and chronic mouse models of cigarette smoke-induced inflammation","volume":"11","author":"Wan","year":"2010","journal-title":"Respir Res"},{"key":"10.1124\/jpet.114.220558_bib39","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.pupt.2013.05.004","article-title":"Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD","volume":"26","author":"Watz","year":"2013","journal-title":"Pulm Pharmacol Ther"},{"issue":"5, Suppl","key":"10.1124\/jpet.114.220558_bib40","doi-asserted-by":"crossref","first-page":"188S","DOI":"10.1378\/chest.121.5_suppl.188S","article-title":"A model of tobacco smoke-induced airflow obstruction in the guinea pig","volume":"121","author":"Wright","year":"2002","journal-title":"Chest"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524189628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524189628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.114.220558","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T17:57:50Z","timestamp":1739987870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524189628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0022356524189628"],"URL":"https:\/\/doi.org\/10.1124\/jpet.114.220558","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CHF6001 II: A Novel Phosphodiesterase 4 Inhibitor, Suitable for Topical Pulmonary Administration\u2014In Vivo Preclinical Pharmacology Profile Defines a Potent Anti-Inflammatory Compound with a Wide Therapeutic Window","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.114.220558","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}